<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060289</url>
  </required_header>
  <id_info>
    <org_study_id>2021-P2-290-01</org_study_id>
    <nct_id>NCT05060289</nct_id>
  </id_info>
  <brief_title>A Prognostic Model for Drug-induced Liver Injury in China</brief_title>
  <acronym>DILI-PM</acronym>
  <official_title>A Prognostic Model for Drug-induced Liver Injury in China : A Multi-center, Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center, non-interventional cohort study is going to conduct to explore&#xD;
      the clinical characteristics, culprit drug(s) or herb(s), outcomes and risk factors of&#xD;
      Drug-induced liver injury (DILI) in China and screen novel serum markers.&#xD;
&#xD;
      A prognostic model incorporating with the novel serum marker(s) for DILI would be established&#xD;
      and validated to imporve the prognosis of patients in China .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Objectives:&#xD;
&#xD;
        1. To establish a standardized multi-center, prospective DILI cohort nationwide and obtain&#xD;
           long-term prognostic data.&#xD;
&#xD;
        2. To establish and verify prognostic model(s) of DILI in China.&#xD;
&#xD;
        3. To explore novel serum biomarkers for the prognosis of DILI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>death/liver transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>DILI has a primary, contributory role for the death (liver-related mortality) or no role for the death (all-cause mortality) .&#xD;
DILI is the primary indication for liver transplantation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>acute liver failure</measure>
    <time_frame>1 year</time_frame>
    <description>Acute liver failure is defined as elevated bilirubin and prolonged international normalized ratio (INR) ≥1.5 accompanied by mental disturbance within 26 weeks after DILI onset without underlying chronic liver diseases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>chronic DILI</measure>
    <time_frame>2 years</time_frame>
    <description>Chronicity is defined as the presence of any one of the following: (i) persistently elevated liver biochemistry indexes; (ii) radiological or histological evidence of persistent liver injury at one year after DILI onset.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recovery</measure>
    <time_frame>2 years</time_frame>
    <description>Recovery status is defined as clinical and biochemical resolution within 1 year after DILI onset, with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤40 U/L, alkaline phosphatase (ALP) ≤150 U/L, and total bilirubin (TB) ≤1.5 upper limits of normal (ULN) (25.65 μmol/L).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Drug-induced Liver Injury</condition>
  <arm_group>
    <arm_group_label>Modeling group</arm_group_label>
    <description>The data of modeling group is used to construct a predictive model of DILI endpoint events.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation group</arm_group_label>
    <description>Validation group is used to validate the predictive model externally.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, liver histopathology (if any)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult with drug-induced liver injury&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. RUCAM ≥6 and met one of the following biochemical conditions: (1) ALT≥5 ULN, (2) or&#xD;
             ALP ≥2 ULN, (3) or ALT≥3 ULN and TBil≥2 ULN.&#xD;
&#xD;
          2. RUCAM between 3-5, five experienced hepatologists in leading site evaluate and vote&#xD;
             the diagnosis of DILI, the case would be enrolled if only ≥4 out of 5 hepatologists&#xD;
             agree with the diagnosis.&#xD;
&#xD;
          3. Onset to enrollment ≤3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hepatotropic viral infection: hepatitis A, B, C, D and E.&#xD;
&#xD;
          2. Non-hepatotropic viral infection: cytomegalovirus (CMV) and Epstein-Barr virus (EBV),&#xD;
             etc.&#xD;
&#xD;
          3. Hypoxic ischemic hepatitis and congestive liver disease.&#xD;
&#xD;
          4. Alcohol consumption: male &gt;40g/d, female &gt;20g/d, and ≥5 years.&#xD;
&#xD;
          5. Biliary obstruction, primary biliary cholangitis; primary sclerosing cholangitis.&#xD;
&#xD;
          6. Autoimmune hepatitis: International Autoimmune Hepatitis Group (IAHG) simplified score&#xD;
             ≥6 or complicated score ≥10, or differentiation from autoimmune hepatitis is&#xD;
             impossible during enrollment.&#xD;
&#xD;
          7. Parasitic infection.&#xD;
&#xD;
          8. Sepsis.&#xD;
&#xD;
          9. Previous liver transplantation or bone marrow transplantation.&#xD;
&#xD;
         10. Pregnancy or lactation.&#xD;
&#xD;
         11. Genetic and metabolic liver diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinyan Zhao</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhengsheng Zou</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing 302 Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing You 'an Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qinghai People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pingying Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qinghai People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoju Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qinzhou First People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liang Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Hospital of Lanzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Luo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei CNPC Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huahua Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hejiaozuo People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hui Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hejiaozuo People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jikang Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hejiaozuo People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Doudou Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qingdao Municipal Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiuju Tian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Hospital of Qingdao University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rongkuan Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Dalian Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Wang</last_name>
    <phone>18810530724</phone>
    <email>wangyanpku@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zikun Ma</last_name>
    <phone>18311270304</phone>
    <email>maazikun0114@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xinyan Zhao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>December 19, 2021</last_update_submitted>
  <last_update_submitted_qc>December 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Xinyan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>prognostic model(s)</keyword>
  <keyword>biomarker(s)</keyword>
  <keyword>endpoint event(s)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chemical and Drug Induced Liver Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

